Abstract:Abstract Purpose: CD11b+Gr1+ MDSC, a subset of bone marrow cells with immune-suppressive and proangiogenic activities, has been shown to mediate resistance to antiangiogenic therapy in various cancer models. The significance of tumor-infiltrating MDSCs in mediating the resistance to sorafenib in hepatocellular carcinoma (HCC) has not been elucidated. Experimental designs: We adopted an orthotopic mouse liver cancer model by implanting BNL murine liver cancer cells in BALB/c mice, which were treated with sorafenib at the dose of 5 mg/Kg/d from day 8 after tumor cells implantation for 1 week or 3 weeks. Results: Both proportion and number of CD11b+Gr1+Ly6G+Ly6Clo MDSCs markedly increased in liver tumors, but not in spleens. This increment of tumor-infiltrating CD11b+Gr1+Ly6G+Ly6Clo MDSCs was found at one week of sorafenib treatment, when intra-tumor levels of multiple proangiogenic factors including VEGF, MCP-1 and IL-6 significantly increased, and the ratios of immune suppressors versus interferon-gamma expressing effectors tilted toward immune-suppression. CD11b+Gr1+Ly6G+Ly6Clo MDSCs isolated from liver tumors treated with sorafenib expressed higher levels of CD115, CD124, CD274 or CCR2 on cell surface and higher transcripts of pro-angiogenic factors, including VEGF, COX2, Bv8/Prok2, STAT3, S100A8, S100A9, or NOX2 than those from liver tumors treated with vehicle. Tumor-derived CD11b+Gr1+Ly6G+Ly6Clo MDSCs from sorafenib-treated mice were capable of suppressing specific tumor cell killing of CD8+ T cells and inducing the generation of immunosuppressive CD4+ T cells. These MDSCs also induced angiogenesis, as demonstrated in increased vascular density and hemoglobin. In sorafenib- treated mice, the concomitant use of anti-IL-6 antibody alleviated the early infiltration of CD11b+Gr1+Ly6G+Ly6Clo MDSCs in liver tumors, decreased the levels of anti-angiogenic factors, reduced vascular density, restored the proliferative activity of tumor-infiltrating T cells and suppressed the liver tumor growth synergistically. Conclusions: Our data indicate that intratumor infiltration of CD11b+Gr1+Ly6G+Ly6Clo MDSCs impaired the therapeutic efficacy of sorafenib through promoting immune-suppression and angiogenesis. Targeting this subset of MDSCs by anti-IL-6 antibody could improve the anti-HCC efficacy of sorafenib.(This work was supported by Grant. NSC 102-2314-B-002 -144 -) Citation Format: Chun-Jung Chang, Yao-Hsu Yang, Chiao-Juno Chiu, Bor-Luen Chiang, Xiao-yi Lee, Chih-Hung Hsu, Ann-Lii Cheng. Therapeutic effect of sorafenib is attenuated by tumor-infiltrating Ly6G+ myeloid-derived suppressor cells (MDSCs) and is restored by anti-interleukin-6 (IL-6) antibody treatment in an orthotopic mouse liver cancer model. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 461. doi:10.1158/1538-7445.AM2015-461

Retraction Note: Combination of Sorafenib and Gadolinium Chloride (gdcl3) Attenuates Dimethylnitrosamine(dmn)-Induced Liver Fibrosis in Rats

Dual GSH-exhausting Sorafenib Loaded Manganese-Silica Nanodrugs for Inducing the Ferroptosis of Hepatocellular Carcinoma Cells.

STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis bythe protein kinase inhibitor sorafenib

Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis

Differential Effects of Sorafenib on Liver Versus Tumor Fibrosis Mediated by Stromal-Derived Factor 1 Alpha/c-X-c Receptor Type 4 Axis and Myeloid Differentiation Antigen-Positive Myeloid Cell Infiltration in Mice.

Layered Double Hydroxides-Loaded Sorafenib Inhibit Hepatic Stellate Cells Proliferation and Activation In Vitro and Reduce Fibrosis In Vivo

Abstract 461: Therapeutic Effect of Sorafenib is Attenuated by Tumor-Infiltrating Ly6G+ Myeloid-Derived Suppressor Cells (mdscs) and is Restored by Anti-Interleukin-6 (IL-6) Antibody Treatment in an Orthotopic Mouse Liver Cancer Model

STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib.

Targeting Tumor-Infiltrating Ly6G+ Myeloid Cells Improves Sorafenib Efficacy in Mouse Orthotopic Hepatocellular Carcinoma.

Sorafenib: A Potential Therapeutic Drug for Hepatic Fibrosis and Its Outcomes.

Sorafenib Ameliorates Renal Fibrosis Through Inhibition of TGF-β-Induced Epithelial-Mesenchymal Transition

Sorafenib Inhibits Renal Fibrosis Induced by Unilateral Ureteral Obstruction via Inhibition of Macrophage Infiltration

Suppression of the expression of multidrug resistance protein in liver cancer cells by sorafenib and the growth of subcutaneous tumor in nude mice model treated by a combination of sorafenib and fluorouracil

Sorafenib Ameliorates Renal Fibrosis Through Inhibition of TGF-β/Smad Pathway

[Suppression of the Growth of Subcutaneous Transplanted Human Liver Cancer and Lung Metastasis in Nude Mice Treated by Sorafenib Combined with Fluorouracil].

Combination of ShuangDan Capsule and Sorafenib Inhibits Tumor Growth and Angiogenesis in Hepatocellular Carcinoma Via PI3K/Akt/mTORC1 Pathway

Sorafenib Delays Recurrence and Metastasis after Liver Transplantation in a Rat Model of Hepatocellular Carcinoma with High Expression of Phosphorylated Extracellular Signal-Regulated Kinase.

Multiwalled Carbon Nanotubes Co-Delivering Sorafenib and Epidermal Growth Factor Receptor Sirna Enhanced Tumor-Suppressing Effect on Liver Cancer.

Ginkgo Biloba Extract Reverses Ccl4-Induced Liver Fibrosis in Rats

MRI Monitoring of Combined Therapy with Transcatheter Arterial Delivery of NK Cells and Systemic Administration of Sorafenib for the Treatment of HCC

Selective therapeutic efficacy of tyrosine kinase inhibitor sorafenib on the restoration of methylglyoxal-induced peritoneal fibrosis